Simultaneously, the expression and phosphorylation of FOXO3a, which is triggered by paclitaxel, has a close relationship with AMPK conditions, making the paclitaxel-induced AMPK/EF1α/FOXO3a axis a signature of chemotherapy in breast cancer [237]. This evidence concerns the gene PRKAA1 and breast carcinoma.